articleThe Lancet OncologyMar 29, 2024GREEN OA

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Cliniques Universitaires Saint-Luc · Institut Gustave Roussy · +28 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

199
total citations
FWCI
94.57
Percentile
100%
References
26
Citations per year

Authors

190

Topics & keywords

Keywords
  • Medicine
  • Pembrolizumab
  • Chemoradiotherapy
  • Placebo
  • Regimen
  • Head and neck squamous-cell carcinoma
  • Clinical endpoint
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding